Court Opinion

ID: 9914838
Source: CourtListenerOpinion
Date Created: 2024-01-03 16:01:23.716032+00
Date Added: 2024-06-11T13:14:47.445937
License: Public Domain

Case: 23-1795   Document: 49     Page: 1   Filed: 01/03/2024

   United States Court of Appeals
       for the Federal Circuit
                 ______________________

                   DEXCOM, INC.,
                   Plaintiff-Appellant

                            v.

      ABBOTT DIABETES CARE, INC., ABBOTT
      DIABETES CARE SALES CORPORATION,
               Defendants-Appellees
              ______________________

                       2023-1795
                 ______________________

     Appeal from the United States District Court for the
 District of Delaware in Nos. 1:21-cv-01699-KAJ, 1:22-cv-
 00605-KAJ, Circuit Judge Kent A. Jordan.
                  ______________________

                Decided: January 3, 2024
                 ______________________

     WILLIAM ADAMS, Quinn Emanuel Urquhart & Sullivan,
 LLP, New York, NY, argued for plaintiff-appellant. Also
 represented by DAVID LEON BILSKER, San Francisco, CA;
 NATHAN HAMSTRA, Chicago, IL; ALEXANDER HALE LOOMIS,
 Boston, MA; VALERIE ANNE LOZANO, I, Los Angeles, CA;
 JOHN W. SHAW, Shaw Keller LLP, Wilmington, DE.

    JASON M. WILCOX, Kirkland & Ellis LLP, Washington,
 DC, argued for defendants-appellees. Also represented by
 WILLIAM H. BURGESS, JOHN C. O'QUINN; AMANDA J. HOLLIS,
Case: 23-1795      Document: 49    Page: 2    Filed: 01/03/2024

 2                  DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.

 Chicago, IL; BENJAMIN ADAM LASKY, ASHLEY ROSS, New
 York, NY, ELLISEN SHELTON TURNER, Los Angeles, CA.
                 ______________________

         Before DYK, HUGHES, and STOLL, Circuit Judges.
 STOLL, Circuit Judge.
      This is an interlocutory appeal from a consolidated case
 between Abbott Diabetes Care, Inc. and Abbott Diabetes
 Care Sales Corp. (collectively, “Abbott”) and DexCom, Inc.
 in the United States District Court for the District of Dela-
 ware. After DexCom sued Abbott for infringing its patents,
 Abbott petitioned for inter partes review of the asserted pa-
 tents before the Patent Trial and Appeal Board. DexCom
 moved for a preliminary injunction to enjoin Abbott from
 proceeding with the inter partes review proceedings based
 on a forum selection clause in a settlement and license
 agreement between the parties. DexCom appeals the dis-
 trict court’s denial of the preliminary injunction. Because
 the district court did not abuse its discretion in denying the
 preliminary injunction, we affirm. 1

     1   After oral argument, DexCom moved to voluntarily
 dismiss its appeal under Rule 42(b)(2) of the Federal Rules
 of Appellate Procedure because it contends an injunction is
 “no longer necessary” in light of the Patent Trial and Ap-
 peal Board’s final written decisions in the inter partes re-
 views at issue. Pl.-Appellant’s Mot. Voluntary Dismissal,
 ECF No. 46 at 1. Abbott opposes, contending that the par-
 ties continue to dispute whether Abbott breached the set-
 tlement and license agreement by filing its IPRs. See ECF
 No. 47.
      We deny the motion. DexCom, as the party asserting
 mootness, bears the burden of demonstrating that
 (1) “there is no reasonable expectation that the alleged vi-
 olation will recur, and (2) interim relief or events have
Case: 23-1795     Document: 49     Page: 3    Filed: 01/03/2024

 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.                  3

                        BACKGROUND
     DexCom and Abbott are competing manufacturers of
 continuous glucose monitoring systems. In 2014, after
 years of patent litigation, DexCom and Abbott entered into
 a settlement and license agreement (Agreement). The
 Agreement included (1) terms for a cross-license for certain
 patents, J.A. 340 § C; (2) a mutual covenant not to sue dur-
 ing a Covenant Period, J.A. 340–45 § D; (3) a mutual cove-
 nant not to Challenge DexCom’s or Abbott’s patents during
 the Covenant Period, J.A. 345–46 § F; and (4) a forum se-
 lection clause identifying the U.S. District Court for the
 District of Delaware as the exclusive jurisdiction “over any
 dispute arising from or under or relating to this Agree-
 ment, to the extent permitted by law,” J.A. 353 ¶ J.4. It
 defined Challenge to mean:
     with respect to any Party’s patents or patent appli-
     cations, directly or indirectly, (a) to assert in any
     court or other competent governmental authority
     that such patents or patent applications are invalid

 completely and irrevocably eradicated the effects of the al-
 leged violation.” Los Angeles Cnty. v. Davis, 440 U.S. 625,
 631 (1979) (cleaned up); see also Sumecht NA, Inc.
 v. United States, 923 F.3d 1340, 1345 n.6 (Fed. Cir. 2019)
 (same). DexCom fails to meet this burden because the
 Board’s final written decisions do not “completely and ir-
 revocably eradicate[]” the potential for DexCom to chal-
 lenge Abbott’s ability to file and participate in inter partes
 reviews in the future. Davis, 440 U.S. at 631. Indeed, the
 parties continue to dispute whether the IPRs were barred
 under the Agreement. For at least these reasons, it is ap-
 propriate to deny the motion to dismiss. See, e.g., In re
 Nexium Antitrust Litig., 778 F.3d 1, 1–2 (1st Cir. 2015)
 (court’s investment in time, existence of draft opinion, and
 parties’ continued disagreement all support denial of vol-
 untary motion to dismiss following oral argument).
Case: 23-1795     Document: 49      Page: 4    Filed: 01/03/2024

 4                 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.

     or unenforceable, (b) to seek in any court or other
     competent governmental authority to narrow or
     change the scope of such patents or patent applica-
     tions, (c) to seek, request, or otherwise take any ac-
     tion that results, or is reasonably expected to result
     in the declaration, initiation or continuation of a
     reexamination, interference or derivation proceed-
     ing, opposition, post-grant review or inter partes re-
     view of such patents, [or] (d) to submit to any court
     or other competent governmental authority prior
     art, evidence, or arguments adverse to the patent-
     ability or validity of any of the other Party’s patents
     or patent applications . . . .
 J.A. 333–34 ¶ A.7 (emphasis added). The Agreement spec-
 ified the Covenant Period was to expire March 31, 2021.
 J.A. 335 ¶ A.11. Meanwhile, the Agreement was set to end
 “the earlier of (i) the date when the last of the Licensed Pa-
 tents expires or (ii) December 31, 2025.” J.A. 351 ¶ I.1.
      After expiration of the Covenant Period, DexCom sued
 Abbott in the Western District of Texas, alleging infringe-
 ment of sixty claims of five of its patents. Abbott moved to
 transfer the case to the District of Delaware, citing the
 Agreement’s forum selection clause. While the motion to
 transfer was pending, Abbott filed a breach-of-contract suit
 against DexCom in Delaware. Among other things, it al-
 leged that DexCom breached the Agreement by suing Ab-
 bott on licensed patents and by filing its suit in Texas in
 violation of the forum selection clause. The Western Dis-
 trict of Texas court transferred DexCom’s infringement
 suit to Delaware, where it was consolidated with Abbott’s
 breach-of-contract suit.
     In April 2022—ten months after DexCom filed its in-
 fringement suit in Texas—Abbott filed eight petitions for
 inter partes review (IPR) of DexCom’s asserted patents.
 DexCom filed preliminary patent owner responses in
Case: 23-1795     Document: 49      Page: 5     Filed: 01/03/2024

 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.                    5

 August 2022, urging the Board not to institute any of the
 IPRs. See, e.g., J.A. 910–92.
     Five months later, DexCom answered with a breach-of-
 contract counter-counterclaim at the district court, alleg-
 ing inter alia that Abbott breached the Agreement’s forum
 selection clause by filing IPR petitions. See Abbott Diabetes
 Care, Inc. v. DexCom, Inc., No. 21-1699, 2023 U.S. Dist.
 LEXIS 69298, at *5–6 (D. Del. Apr. 12, 2023) (Decision); see
 also J.A. 320–21 ¶ 358. Prior to this time, DexCom had
 consistently taken the position that the claims of the as-
 serted patents were not licensed, which would render the
 forum selection clause inapplicable. On October 14, 2022,
 Abbott moved to dismiss DexCom’s counter-counterclaim.
      Then, on October 25, 2022—six months after Abbott
 filed its IPR petitions—DexCom moved for a preliminary
 injunction, requesting the district court prohibit Abbott
 from proceeding with the IPRs. See J.A. 327–28. After an-
 alyzing the appropriate preliminary injunction factors, in-
 cluding whether DexCom “establish[ed] that [it] is likely to
 succeed on the merits, that [it] is likely to suffer irreparable
 harm in the absence of preliminary relief, that the balance
 of equities tips in [its] favor, and that an injunction is in
 the public interest,” the district court denied the prelimi-
 nary injunction. Decision, 2023 U.S. Dist. LEXIS 69298,
 at *20 n.9, *25–27 (quoting Winter v. Nat. Res. Def. Coun-
 cil, Inc., 555 U.S. 7, 20 (2008)). The court assumed for pur-
 poses of the motion that DexCom met the first preliminary
 injunction factor, i.e., that DexCom had shown a likelihood
 of success. Id. at *20–21.
     Turning to the second factor—irreparable harm—the
 district court found this factor favored denial of an injunc-
 tion because DexCom actively participated in IPR proceed-
 ings for six months before seeking injunctive relief. Id.
 at *21–24. The court reasoned that DexCom’s six-month
 delay “negat[es] the idea of irreparability.” Id. at *23
 (quoting Pfizer, Inc. v. Teva Pharms. USA, Inc., 429 F.3d
Case: 23-1795     Document: 49     Page: 6    Filed: 01/03/2024

 6                 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.

 1364, 1382 (Fed. Cir. 2002)). The court explained that
 “[a]lthough DexCom says the harm it faces stems from the
 PTAB making a validity determination based on a lower
 standard of proof, DexCom obviously knew of that potential
 harm as soon as it learned about Abbott’s IPR petitions,
 and it could have acted accordingly.” Id. at *23.
     The district court found that the third factor—balance
 of hardship—favored denial because DexCom’s incon-
 sistent legal positions (previously arguing that the patents
 were not licensed but now seeking a preliminary injunction
 by asserting that the patents were licensed) and use of Pa-
 tent Trial and Appeal Board’s (PTAB) resources (by partic-
 ipating in the IPRs) cut against equitable relief. Id. at *24–
 26. For the fourth factor—public interest—the district
 court explained that although “‘no public interest [is]
 served by excusing a party’s violation of its previously ne-
 gotiated contractual undertaking to litigate in a particular
 forum,’ it is yet to be determined whether the IPRs, in fact,
 violate the” Agreement. Id. at *26 (quoting Gen. Protecht
 Grp., Inc. v. Leviton Mfg. Co., 651 F.3d 1355, 1366
 (Fed. Cir. 2011)). It then determined that “[a]t this point”
 the public interest in preventing invalid patents and allow-
 ing the PTAB to complete its proceedings weighed against
 an injunction. See id.
     DexCom appeals from the district court’s interlocutory
 order. We have jurisdiction under 28 U.S.C. §§ 1292(c)(1),
 1295(a)(1).
                         DISCUSSION
     We review a denial of a preliminary injunction under
 regional circuit law—here, the law of the Third Circuit.
 Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.,
 25 F.4th 998, 1004 (Fed. Cir. 2022). The Third Circuit re-
 views such denials for an abuse of discretion and reviews
 underlying legal errors de novo. Id.; Adams v. Freedom
 Forge Corp., 204 F.3d 475, 484 (3d Cir. 2000). “To meet the
 abuse-of-discretion standard, the moving party must show
Case: 23-1795     Document: 49     Page: 7    Filed: 01/03/2024

 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.                  7

 that the district court has made ‘a clear error of judgment
 in weighing relevant factors or in basing its decision on an
 error of law or on clearly erroneous factual findings.’”
 Bayer CropScience AG v. Dow AgroSciences LLC, 851 F.3d
 1302, 1306 (Fed. Cir. 2017) (quoting Mentor Graphics Corp.
 v. Quickturn Design Sys., Inc., 150 F.3d 1374, 1377
 (Fed. Cir. 1998)).
     The court considers the following four factors in evalu-
 ating a motion for a preliminary injunction: “(1) whether
 the moving party has shown a reasonable likelihood of suc-
 cess on the merits; (2) whether the moving party will suffer
 irreparable harm in the absence of a preliminary injunc-
 tion; (3) whether the balance of hardships tips in the mov-
 ing party’s favor; and (4) the impact of a preliminary
 injunction on the public interest.” Nippon Shinyaku,
 25 F.4th at 1005.
     The first factor, whether DexCom is likely to succeed
 on the merits of its breach-of-contract counter-counter-
 claim, requires interpretation of the Agreement. Specifi-
 cally, we must determine whether the Agreement’s forum
 selection clause bars the filing of IPRs after the Covenant
 Period. Thus, this appeal presents “a question of contract
 interpretation under Delaware law, which we review de
 novo.” Studiengesellschaft Kohle, M.B.H. v. Hercules, Inc.,
 105 F.3d 629, 632 (Fed. Cir. 1997); J.A. 356 ¶ K.7 (“This
 Agreement . . . shall be construed, governed, and inter-
 preted in accordance with the laws of the State of Dela-
 ware . . . .”). The district court assumed for purposes of the
 motion that this factor weighed in favor of an injunction. 2

     2   The district court has since held that Abbott’s IPR
 petitions did not violate the Agreement’s forum selection
 clause, reasoning that IPR petitions could only be filed at
 the PTAB and thus could not be brought in the District of
 Delaware. See ECF No. 21, Ex. 2 (Pretrial Tr. at 88:25–
 89:06).
Case: 23-1795     Document: 49     Page: 8    Filed: 01/03/2024

 8                 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.

 Our review of the Agreement compels us to conclude other-
 wise.
     Under Delaware law, contract interpretation requires
 that the “construction . . . be that which would be under-
 stood by an objective, reasonable third party.” Estate of
 Osborn v. Kemp, 991 A.2d 1153, 1159 (Del. 2010). We are
 to read the contract “as a whole” and “give each provision
 and term effect, so as not to render any part of the contract
 mere surplusage.” Id. (quoting Kuhn Const., Inc. v. Dia-
 mond State Port Corp., 990 A.2d 393, 396–97 (Del. 2010)).
 Our interpretation “requires all contract provisions to be
 harmonized and given effect where possible.” Martin Mari-
 etta Materials, Inc. v. Vulcan Materials Co., 68 A.3d 1208,
 1225 (Del. 2012), as corrected (July 12, 2012).
     Under the heading “F. No Challenge Covenants and
 Exceptions Thereto,” the Agreement’s no-challenge cove-
 nants state that “[d]uring the Covenant Period,” DexCom
 and Abbott “shall not Challenge” each other’s patents or
 patent applications provided that the parties are comply-
 ing with the Agreement. J.A. 345 §§ F.1–2. This section of
 the Agreement also contains the following exceptions:
     3. However, each Party reserves its rights and is
     permitted to Challenge any patent or patent appli-
     cation that is being asserted (or threatened to be
     asserted) against it or its products.
     4. Further, each Party reserves its rights and is
     permitted to Challenge any of the patents of the
     other Party if there is a statute, regulation, or rule
     that sets a deadline to make the Challenge.
 J.A. 346.
     Section F.4 also lists nonlimiting examples of Chal-
 lenges contemplated by the exception, such as post grant
 review or interference proceedings. J.A. 346. As noted su-
 pra at 3, the Agreement’s definition of Challenge expressly
Case: 23-1795    Document: 49      Page: 9    Filed: 01/03/2024

 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.                 9

 includes inter partes review of the parties’ patents.
 J.A. 333 § A.7.
     We are to interpret contract terms as an objective, rea-
 sonable third party would and, on its face, the forum selec-
 tion clause applies during the Agreement’s entire term,
 including during the Covenant Period. Under the heading,
 “Choice of Forum,” the forum selection clause states: “The
 United States Federal District Court for the District of Del-
 aware shall have exclusive jurisdiction over any dispute
 arising from or under or relating to this Agreement, to the
 extent permitted by law.” J.A. 353 § J.4. Nothing in the
 forum selection clause or elsewhere in the Agreement sug-
 gests an intent to restrict the forum selection clause to the
 period after the Covenant Period.
      Although the parties dispute whether the filing of IPRs
 was permissible after the Covenant Period, sections F.3
 and F.4 indisputably allowed IPR filings during the Cove-
 nant Period under certain conditions. See Oral Arg.
 at 3:44–3:54 (DexCom admission), 23:40–23:50 (Abbott ad-
 mission),        https://oralarguments.cafc.uscourts.gov/de-
 fault.aspx?fl=23-1795_09052023.mp3.           It necessarily
 follows that because the forum selection clause governs
 both during and after the Covenant Period, the clause can-
 not operate to prohibit the filing of IPRs after the Covenant
 Period if it allowed them during the Covenant Period. See
 Oral Arg. at 2:22–3:00; see also Martin Marietta, 68 A.3d
 at 1225. We are not persuaded by DexCom’s suggestion
 that the forum selection clause has a different interpreta-
 tion during the Covenant Period versus after the Covenant
 Period. Nothing in the Agreement supports such an inter-
 pretation. We are similarly unpersuaded by DexCom’s ar-
 gument that the forum selection clause does not apply
 during the Covenant Period because, as noted above, noth-
 ing in the Agreement indicates as much.
     Given the specific language in the Agreement in this
 case, DexCom’s reliance on our decisions in Texas
Case: 23-1795     Document: 49      Page: 10    Filed: 01/03/2024

 10                 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.

 Instruments Inc. v. Tessera, Inc., 231 F.3d 1325 (Fed. Cir.
 2000); General Protecht, 651 F.3d at 1355; and Dodocase
 VR, Inc. v. MerchSource, LLC, 767 F. App’x 930 (Fed. Cir.
 2019) (nonprecedential) to support its argument that the
 forum selection clause precludes IPR proceedings is mis-
 placed. Although we held that the specific forum selection
 clauses at issue in those cases prohibited filing a proceed-
 ing outside the stipulated forum, 3 those cases lacked a key

      3   In Texas Instruments, the district court denied a
 preliminary injunction to prevent the defendant from par-
 ticipating in an International Trade Commission (ITC) in-
 fringement action because although the parties’ license
 agreement required that “any litigation . . . relating to this
 Agreement shall take place in California,” Texas Instru-
 ments had “not established a likelihood of proving that
 [Tessera’s] action before the ITC is litigation.” 231 F.3d
 at 1327–28. In reversing the district court’s denial, we ex-
 plained that in the field of patent law, which was relevant
 to the license at issue, “‘litigation’ does not exclude ITC pro-
 ceedings under section 337.” Id. at 1330.
      In General Protecht, the district court granted a pre-
 liminary injunction to prevent the defendant from litigat-
 ing in the Northern District of California or at the ITC.
 651 F.3d at 1358. There, the forum selection clause stated
 that “[a]ny dispute between the Parties relating to or aris-
 ing out of this [Settlement Agreement] shall be prosecuted
 exclusively in the United States District Court for the Dis-
 trict of New Mexico.” Id. We found no abuse of discretion
 in the district court’s grant of the injunction because the
 dispute indisputably “relate[d] to or ar[o]se[] out of” the set-
 tlement agreement. Id. at 1359.
      In Dodocase, the district court also granted a prelimi-
 nary injunction to prohibit IPR proceedings, specifically
 finding that “Dodocase was likely to succeed on its claim
 that MerchSource filed the PTAB petitions in violation of
 the forum selection clause of the” license agreement.
Case: 23-1795    Document: 49      Page: 11    Filed: 01/03/2024

 DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.                 11

 circumstance present here—that the Agreement allowed
 the filing of IPR petitions under certain circumstances not-
 withstanding the existence of the forum selection clause.
     We therefore conclude DexCom cannot succeed on its
 breach-of-contract counter-counterclaim. Although the
 district court erred in assuming DexCom proved a likeli-
 hood of success, this error was harmless as our conclusion
 that DexCom failed to demonstrate a likelihood of success
 favors the district court’s ultimate denial of the prelimi-
 nary injunction. See, e.g., Nippon Shinyaku, 25 F.4th
 at 1005 (“[U]nder both Federal Circuit and Third Circuit
 precedent, the first factor—i.e., likelihood of success on the
 merits—is a necessary showing to establish entitlement to
 a preliminary injunction.”). Moreover, because DexCom
 cannot succeed on the merits in its breach-of-contract coun-
 ter-counterclaim under our legal interpretation of the
 Agreement, it is not entitled a preliminary injunction, and
 we need not address the remaining preliminary injunction
 factors. Reebok Int’l Ltd. v. J. Baker, Inc., 32 F.3d 1552,
 1555–56 (Fed. Cir. 1994) (“A movant seeking a preliminary
 injunction must establish a reasonable likelihood of success
 on the merits . . . .”); see also Nichia Corp. v. Everlight
 Ams., Inc., 855 F.3d 1328, 1344 (Fed. Cir. 2017) (“Because
 [the movant] failed to establish one of the four equitable
 factors, the court did not abuse its discretion in denying
 [the movant]’s request for an injunction.”). Accordingly, we

 767 F. App’x at 934. The forum selection clause there re-
 quired that “disputes shall be litigated before the courts in
 San Francisco County or Orange County, California.” Id.
 at 932 (cleaned up). The agreement prohibited the non-mo-
 vant’s ability to “challenge the validity or enforceability of
 the Licensed IP.” Id. We explained that the district court
 “did not err in concluding that” the forum selection clause
 “encompassed PTAB proceedings.” Id. at 935.
Case: 23-1795    Document: 49     Page: 12    Filed: 01/03/2024

 12                DEXCOM, INC. v. ABBOTT DIABETES CARE, INC.

 affirm the district court’s denial of a preliminary injunc-
 tion.
                        CONCLUSION
      The district court did not abuse its discretion in deny-
 ing the motion for a preliminary injunction. We therefore
 affirm.
                        AFFIRMED